Dexmedetomidine and hydromorphone: A novel pain management strategy for the oncology ward setting during anti‐GD2 immunotherapy for high‐risk neuroblastoma in children
Pediatric Blood & Cancer2014Vol. 62(1), pp. 29–34
Citations Over TimeTop 22% of 2014 papers
Abstract
Dexmedetomidine infusion may be an effective and safe pain management adjunct to opioid therapy for the pain of ch14.18 infusion.
Related Papers
- → Incidence and risk factors of bradycardia in pediatric patients undergoing intranasal dexmedetomidine sedation(2019)38 cited
- → Bradycardia During Dexmedetomidine and Therapeutic Hypothermia(2008)40 cited
- → Severe Hypertensive Response to Atropine Therapy for Bradycardia Associated with Dexmedetomidine: Case Report and Literature Review(2024)10 cited
- → Median Effective Dose of Dexmedetomidine Inducing Bradycardia in Elderly Patients Determined by Up-and-Down Sequential Allocation Method(2022)8 cited
- → Changes in expression of Cx45 and Cx40 in sinoatrial node during dexmedetomidine-induced sinus bradycardia in rats(2019)1 cited